Abstract:Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide; 82% of the cases occur in developing countries, with 55% occurring in China [1]. Liver transplantation (LT), a potentially curative thera peutic modality of HCC, allows radical extirpation of the cancer and restores normal liver function. There is increasing evidence that, in the long term, LT will be the best therapeutic option for cirrhosis-associated HCC [2]. Unfortunately, the recurrence rate is high in HCC patients who undergo LT, which markedly reduces the longterm and medium-term survival of HCC patients [3]. Therefore, risk estimation of post-transplant tumor recurrence is an essential element in selecting a subset of HCC patients for LT. In clinical practice, this risk estimation is based on the number and size of the nodules, and microscopic/macroscopic vascular invasion; and selection criteria for LT have been established to select HCC patients according to these clinical features. The Milan criteria proposed by Mazzaferro and his colleagues – a single lesion of 5 cm or smaller in diameter, or three lesions each smaller than 3 cm in diameter, and without macroscopic vascular invasion – have been accepted worldwide for identifying candidates with good prognosis and low recurrence rates [4]. The Milan criteria were chosen in an attempt to minimize the difference in outcomes between transplanted HCC patients and those who did not have HCC, and these criteria have been adopted for organ allocation in the USA and in Europe [5,6]. Despite their proven utility, many recent data have suggested that these criteria are too restrictive, and many patients with tumor burdens outside the Milan criteria may potentially benefit from LT. Moreover, limiting LT to HCC patients within the Milan criteria may be unjust for those outside of the criteria who could have a favorable outcome with LT. Several expansions of the Milan criteria have been proposed. Yao and coworkers at the University of California, San Francisco (UCSF; CA, USA) reported that LT candidates with a solitary tumor of 6.5 cm in diameter or smaller, or three or fewer nodules with the largest lesion no larger than 4.5 cm in diameter, and a total tumor diameter no larger than 8 cm (the so-called UCSF criteria) achieved excellent results following LT that were not different from those for HCC patients within the Milan criteria [7]. Although the UCSF criteria have been validated by several groups [8], these criteria have not been accepted unanimously, which may be related to the results of a large multi center study that suggested the UCSF criteria to be associated with a 5-year survival rate of less than 50% when applied to preoperative evaluation [9]. In addition, the UCSF criteria allow LT for large tumors, which have been proven to be associated with post-transplant metastatic recurrence [10]. Lastly, both the Milan and the UCSF criteria exclude those patients with more than three nodules, who may obtain good outcomes if the tumors are of a reasonable size. Toso and his colleagues proposed an expansion of the current allocation criteria Zhi Dai, PhD Liver Cancer Institute, Shanghai 200032, PR China dai.zhi@zs-hospital.sh.cn

Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation

Relationship Between Clinicopathologic Features and Neoplasm Recurrence,prognosis in Hepatocellular Carcinoma after Liver Transplantation

A Single‐center Retrospective Analysis of Liver Transplantation on 255 Patients with Hepatocellular Carcinoma

Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience

Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation

Comparison of Survival and Tumor Recurrence Rates in Patients Undergoing Liver Transplantation for Hepatitis B-related Hepatocellular Carcinoma Using Milan, Shanghai Fudan and Hangzhou Criteria.

Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a singlecenter study.

Preventive Chemotherapy for Hepatocellular Carcinoma Exceeding Milan Criteria after Fiver Transplantation

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study.

O-2 EVALUATION OF RISK FACTORS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION

AGH SCORE PREDICTS RECURRENCE AND RESPONSE TO ADJUVANT-TARGETED THERAPY IN HBV RELATED HCC AFTER LIVER TRANSPLANTATION

Prognostic Indicators for Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma and Related Molecular Targeted Therapy.

Expanded Criterion for Hepatocellular Carcinoma in Liver Transplantation

Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation

Histological differentiation predicts post-liver transplantation survival time.

[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Hangzhou Experience

The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma

[Influence of Tumor Characteristics on the Outcome of Liver Transplantation among Patients with Hepatocellular Carcinoma].

Analysis of the risk factors influencing the prognosis of patients with recurrent hepatocellular carcinoma after liver transplantation within Fudan criteria and summary of relevant clinical experience